Business
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 Halle (Saale) / Munich, Germany, November 25, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its third quarter financial results for the period ended September 30, 2025 and
About this update from Vivoryon Therapeutics N.v.
[{"type":"image","alt":"Vivoryon Therapeutics N.V.","displaySize":"","headline":null,"caption":"Vivoryon Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iv4MFFdTq5UwH.s30pVCjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c","width":300,"height":96}},"lazy":false},{"type":"text","content":"Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025","length":107,"tagName":"p"},{"type":"text","content":"Halle (Saale) / Munich, Germany, November 25, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its third quarter financial results for the period ended September 30, 2025 and provide a corporate update on Thursday, December 4, 2025. The Company will host a conference call and webcast open to the public.Conference call detailsDate: December 4, 2025Time: 3:00 pm CET / 9:00 am ESTThe conference call will be available via phone and webcast. The live audio webcast of the call will be available on Vivoryon´s website at: https://www.vivoryon.com/news-and-events/presentations-webcasts/","length":808,"tagName":"p"},{"type":"text","content":"To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website: https://register-conf.media-server.com/register/BI375e056b91ee4184ab17c7212371dfda","length":260,"tagName":"p"},{"type":"text","content":"It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance.","length":138,"tagName":"p"},{"type":"text","content":"###","length":3,"tagName":"p"},{"type":"text","content":"About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion f...